ArticleCancer letters2011
Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.
Article in Cancer letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Induction of the STING-dependent DNA damage pathway by cucurbitacin B enhances immunotherapy efficacy in osteosarcoma.Iranian journal of basic medical sciences · 2025Article
- Review
- Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms.Journal of translational medicine · 2022Review
- Cucurbitacin-B Exerts Anticancer Effects through Instigation of Apoptosis and Cell Cycle Arrest within Human Prostate Cancer PC3 Cells via Downregulating JAK/STAT Signaling Cascade.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Reactive Oxygen Species-Responsive Nanococktail With Self-Amplificated Drug Release for Efficient Co-Delivery of Paclitaxel/Cucurbitacin B and Synergistic Treatment of Gastric Cancer.Frontiers in chemistry · 2022Article
- Article
- Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.Chinese medicine · 2019Review
- Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.Oncotarget · 2017Article
- STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.International journal of oncology · 2016Article
- mTOR: An attractive therapeutic target for osteosarcoma?Oncotarget · 2016Review
- Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis.American journal of human genetics · 2016Article
- Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Cucurbitacin B induces DNA damage and autophagy mediated by reactive oxygen species (ROS) in MCF-7 breast cancer cells.Journal of natural medicines · 2015Article
- Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines.Journal of orthopaedic surgery and research · 2015Article
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.International journal of cancer · 2015Article
- Cucurbitacin E Induces Autophagy via Downregulating mTORC1 Signaling and Upregulating AMPK Activity.PloS one · 2015Article
- In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B.PloS one · 2015Article
- Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.Molecular carcinogenesis · 2014Article
- Genomic and molecular characterization of esophageal squamous cell carcinoma.Nature genetics · 2014Article
- The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.International journal of cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
We investigated the use of cucurbitacin B, a plant-derived tetracyclic triterpenoid, as a single agent or in combination with methotrexate (MTX) for human osteosarcoma (OS) treatment. Cucurbitacin B showed antiproliferative activity against seven human OS cell lines in vitro accompanying G2/M cell cycle arrest, apoptosis, and inhibition of ERK, Akt, and mTOR proteins. Cucurbitacin B in combination with MTX synergistically inhibited OS cell growth in vitro. Low-dose cucurbitacin B (LD-CuB, 0.5 mg/kg body weight) or low-dose MTX (LD-MTX, 150 mg/kg) failed to decrease the size of human OS xenografts in nude mice. However, combined therapy at identical concentrations inhibited tumor growth by 62% vs. LD-CuB and 81% vs. LD-MTX (p<0.001). Strikingly, the effect persisted even when the dose of MTX was decreased by two thirds (VLD-MTX, 50 mg/kg). In conclusion, cucurbitacin B alone or in combination with MTX shows promising antiproliferative activity against human OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.